Dr. Edward R. Dabrowski, M.D.
Physical Medicine & Rehabilitation (PM&R) (Physical Medicine & Rehabilitation Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (1980)
- Years since graduation
- 46
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 137
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1980Medical school: Wayne State University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Physical Medicine & Rehabilitation Physician primary
MI license 043735
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Physical Medicine & Rehabilitation (PM&R) per capita by county →
Where they work
Hospitals
- Beaumont Hospital Royal Oak Royal Oak, MI
- Beaumont Hospital, Troy Troy, MI
- Beaumont Hospital - Grosse Pointe Grosse Pointe, MI
Medical groups
- Beaumont Medical Group- Specialty Services (847 clinicians)
- Glendale Neurological Associates P C (40 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 137
- Services billed
- 45,186
- Patients’ average age
- 45
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 29,600 | 31 |
| Injection, abobotulinumtoxina, 5 units | 13,320 | 27 |
| Established patient office or other outpatient visit, 20-29 minutes | 206 | 93 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 124 | 48 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 119 | 52 |
| Established patient office or other outpatient visit, 30-39 minutes | 36 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 67 payments worth $21,326 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $8,235 |
|---|---|
| AbbVie Inc. | $6,574 |
| Acadia Pharmaceuticals Inc | $5,778 |
| Bayer HealthCare Pharmaceuticals Inc. | $236 |
| Biogen, Inc. | $162 |
| Neurelis, Inc. | $115 |
| Merz Pharmaceuticals, LLC | $43.94 |
| Janssen Biotech, Inc. | $36.04 |
| Compensation for services other than consulting (speaking, faculty) | $10,300 |
|---|---|
| Consulting Fee | $8,150 |
| Food and Beverage | $2,484 |
| Travel and Lodging | $392 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 9, 2025 | Consulting Fee | $4,800 |
| Ipsen Biopharmaceuticals, Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Dysport · Neurology | $3,685 |
| Ipsen Biopharmaceuticals, Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Dysport · Neurology | $2,010 |
| Acadia Pharmaceuticals Inc Sep 15, 2025 | Consulting Fee ACP-101 · HYPERPHAGIA IN PRADER-WILLI SYNDROME | $1,950 |
| Acadia Pharmaceuticals Inc Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) ACP-101 · HYPERPHAGIA IN PRADER-WILLI SYNDROME | $1,950 |
| AbbVie Inc. Jan 13, 2025 | Consulting Fee BOTOX · BOTOX THERAPEUTIC | $1,400 |
| Ipsen Biopharmaceuticals, Inc Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) Dysport · Neurology | $1,005 |
| Acadia Pharmaceuticals Inc Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $550 |
| Acadia Pharmaceuticals Inc Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $550 |
| Acadia Pharmaceuticals Inc Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $550 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) Dysport · Neurology | $1,005 |
| AbbVie Inc. Dec 9, 2025 | Consulting Fee | $4,800 |
| Ipsen Biopharmaceuticals, Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Dysport · Neurology | $3,685 |
| Ipsen Biopharmaceuticals, Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Dysport · Neurology | $2,010 |
| Acadia Pharmaceuticals Inc Sep 15, 2025 | Consulting Fee ACP-101 · HYPERPHAGIA IN PRADER-WILLI SYNDROME | $1,950 |
| Acadia Pharmaceuticals Inc Sep 15, 2025 | Compensation for services other than consulting (speaking, faculty) ACP-101 · HYPERPHAGIA IN PRADER-WILLI SYNDROME | $1,950 |
| Acadia Pharmaceuticals Inc Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $550 |
| Acadia Pharmaceuticals Inc Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $550 |
| Acadia Pharmaceuticals Inc Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $550 |
| Ipsen Biopharmaceuticals, Inc Feb 7, 2025 | Travel and Lodging Dysport · Neurology · travel to Washington, DC · in-kind | $392 |
| AbbVie Inc. Jan 13, 2025 | Consulting Fee BOTOX · BOTOX THERAPEUTIC | $1,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $30,895 in research payments for these studies, mostly to the institutions running them.
- A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
Ipsen Pharma Sas · Completed · NCT04936542
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.